Investor News no. 1/2007
To OMX Nordic Exchange Copenhagen Copenhagen, November 2, 2007
Investor News: Curalogic has moved to a new address
From November 1, 2007 Curalogic has moved to a new and bigger office which
fulfils the increased level of activities and growth in the organisation.
The company's new address, telephone and fax number are:
Curalogic A/S
Landemaerket 11, 1st floor
DK-1119 Copenhagen K
Denmark
Tel. +45 99 99 24 00
Fax +45 99 99 24 24
Yours sincerely
Curalogic A/S
For additional information, please contact:
Peter Moldt, President and CEO Tel +45 99 99 24 00, mobile +45 2625 0422
Helle Busck Fensvig, EVP and CFO Tel +45 99 99 24 00, mobile +45 2070 5537
About Curalogic
Curalogic is a Danish biopharmaceutical company listed on the OMX Nordic
Exchange (CUR.CO). Curalogic develops innovative pharmaceuticals for the
treatment of allergy. By combining the best of two worlds - the efficacy of
immunotherapy combined with the safety and patient convenience of symptomatic
treatments - Curalogic aims to develop a novel and user-friendly form of
allergy treatment, and make it the preferred type of allergy treatment among
patients. Curalogic has a broad and mature pipeline with a product for
treatment of ragweed allergy in Phase III, a product for treatment of grass
allergy ready for Phase III, a product for treatment of cat allergy in Phase II
and a product for treatment of house dust mite allergy preparing for clinical
trials.
